1Koherman OG,Kim DD,Shen L,et al.Pharmacokineties,phar-macodyna,and safety of exenatide in patients with type 2 diabetes mellitus.Am J Health Syst Pham,2005,62:173-181.
2Buse JB,Henry RR,Han J,et al.Effects of exenatide(exendin-4) on glycemic control over 30 weeks in sulfonyluiea-treated patients with type2 diabetes.Diabetes Care,2004,27:2628-2635.
同被引文献14
1Negis Y,Aytan N,Ozer N,et al. The effect of tocopherylphos- phates on atherosclerosis progression in rabbits fed with a higheholesterol diet[J]. Arch Physiol Biochem,2006(450) :63- 66.
2Buteau J,EI-Assaad W, Rhodes C J, et al. Glucagon-like pep- tide-1 prevents beta cell glueolipotoxicity[J]. Diabetes, 2008, 57:1205-1215.
